The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis

Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis

July 15, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

EULAR 2022 (VIRTUAL)—It is reassuring for patients and physicians when the presentation and treatment of a disease follow the course outlined in medical textbooks. However, the real world is often much more complicated than an idealized scenario, and clinicians must think critically and creatively about how to care for patients with difficult-to-manage disease.

You Might Also Like
  • Janus Kinase Inhibitors Promising for Difficult-to-Treat RA
  • Treat Rheumatoid Arthritis to Target
  • Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA
Also By This Author
  • The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

At the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR), Jacob M. van Laar, MD, PhD, professor of rheumatology, University Medical Center Utrecht, the Netherlands, provided an instructive lecture on the subject of difficult-to-treat rheumatoid arthritis (RA).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Challenging Conditions

Dr. van Laar

Dr. van Laar began his presentation with a discussion of patient characteristics that may make efficacious treatment of RA challenging. Certain medical comorbidities may cause disease-modifying anti-rheumatic drugs (DMARDs) to be less effective and may increase the risk of adverse drug reactions. Also, medical comorbidities could hamper a clinician’s ability to properly grade RA disease activity, leading to inappropriate treatment decisions.

Examples: Data indicate fibromyalgia can be common in patients with severe RA.1 Obesity can decrease the effectiveness of treatments, worsen subjective measures of disease activity, reduce the likelihood of achieving remission in early disease, reduce the probability of sustained remission and worsen long-term outcomes in RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In addition to medical comorbidities, Dr. van Laar described work that has demonstrated a pauci-immune pathotype that can often be seen when synovial biopsies are performed in patients with difficult-to-treat RA. In these patients, the synovitis seems to be driven by stromal cell pathology, and these cells are not affected by the conventional drugs used to treat RA.

What Is Difficult-to-Treat RA?

Before proceeding with his talk, Dr. van Laar helped provide a clear definition of what may constitute difficult-to-treat RA. He noted that patients in this category should have failed to respond to at least two biologic or targeted synthetic DMARDs with different mechanisms of action after having already failed to respond to conventional synthetic DMARDs. Patients with difficult-to-treat RA may also have signs suggestive of active or progressive disease, namely one or more of the following: at least moderate disease activity, as measured by the Clinical Disease Activity Score or other tools; active synovitis on exam; elevated inflammatory markers or new erosive disease on imaging; the inability to taper glucocorticoids to <7.5 mg of prednisone per day; and/or perceived reduction in quality of life. Finally, the management of symptoms should be perceived by patients and/or rheumatologists as problematic.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: EULAR, EULAR 2022, patient care, RA Resource Center, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Janus Kinase Inhibitors Promising for Difficult-to-Treat RA
  • Treat Rheumatoid Arthritis to Target
  • Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA
  • Predicting the Future: Prognostication in Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)